← Back to Search

Prostaglandin Analog

Latanoprost for Glaucoma and Ocular Hypertension

Phase 1
Recruiting
Led By David S Friedman, MD, PhD, MPH
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 - 14 weeks

Summary

This trial is testing a novel contact lens drug delivery system with latanoprost to lower eye pressure. It will assess safety, tolerability, comfort & feasibility of the new method compared to eye drops.

Eligible Conditions
  • Glaucoma
  • Ocular Hypertension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 - 14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 - 14 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy assessed by changes in intraocular pressure - Phase B
Incidence of Treatment-Emergent Adverse Events as assessed by ocular infection, corneal epithelial defects, or cystoid macular edema - Phase A
Eye Infection
Secondary study objectives
Preliminary efficacy - Phase A: % change in IOP from baseline
Tolerability and comfort: questionnaire

Side effects data

From 2016 Phase 4 trial • 379 Patients • NCT02017327
1%
myocardial infarction
1%
hypotension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lumigan 0.01%
Monoprost
Lumigan 0.03% Unit Dose

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Latanoprost contact lensExperimental Treatment1 Intervention
The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop.
Group II: Topical LatanoprostPlacebo Group1 Intervention
The placebo arm will have a commercial contact lens with no drug with a nightly 0.005% latanoprost drop.

Find a Location

Who is running the clinical trial?

Massachusetts Eye and Ear InfirmaryLead Sponsor
108 Previous Clinical Trials
13,003 Total Patients Enrolled
6 Trials studying Glaucoma
373 Patients Enrolled for Glaucoma
Harvard UniversityOTHER
233 Previous Clinical Trials
473,900 Total Patients Enrolled
David S Friedman, MD, PhD, MPHPrincipal InvestigatorMassachusetts Eye and Ear

Media Library

Latanoprost (Prostaglandin Analog) Clinical Trial Eligibility Overview. Trial Name: NCT04500574 — Phase 1
Glaucoma Research Study Groups: Topical Latanoprost, Latanoprost contact lens
Glaucoma Clinical Trial 2023: Latanoprost Highlights & Side Effects. Trial Name: NCT04500574 — Phase 1
Latanoprost (Prostaglandin Analog) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04500574 — Phase 1
~12 spots leftby Nov 2025